Recent advances in cancer immunotherapy—ranging from immune-checkpoint blockade
therapy to adoptive cellular therapy and vaccines—have revolutionized cancer treatment …

Cancers are highly complex diseases that are characterized by not only the overgrowth of
malignant cells but also an altered immune response. The inhibition and reprogramming of …

High expression of PD-L1 in tumor cells contributes to tumor immune evasion. However,
whether PD-L1 expression in tumor cells is regulated by the availability of nutrients is …

Protein kinases regulate nearly all aspects of cell life, and alterations in their expression, or
mutations in their genes, cause cancer and other diseases. Here, we review the remarkable …

Background Immunotherapy has determined unprecedented long-term responses in several
hematological and solid tumors. In the MOUSEION-03 study, we conducted a meta-analysis …

A paradigm shift in the understanding of the exhausted CD8+ T cell (Tex) lineage is
underway. Originally thought to be a uniform population that progressively loses effector …

The tumor microenvironment (TME) is a heterogeneous, complex organization composed of
tumor, stroma, and endothelial cells that is characterized by cross talk between tumor and …

Immune checkpoint therapy via PD-1 antibodies has shown exciting clinical value and
robust therapeutic potential in clinical practice. It can significantly improve progression-free …

Simple Summary The mitogen-activated protein kinase/extracellular signal-regulated kinase
(MAPK/ERK) signaling pathway is frequently activated in liver cancer, which is one of the …

A photothermal genome‐editing strategy is described to improve immune checkpoint
blockade (ICB) therapy by CRISPR/Cas9‐mediated disruption of PD‐L1 and mild …